BioDelivery Sciences International logo
BioDelivery Sciences International BDSI
report update icon

Quarterly report 2021-Q3
added 06-06-2026

BioDelivery Sciences International Financial Statements 2021-2008 | BDSI

Annual Financial Statements BioDelivery Sciences International

2021 2020 2019 2018 2017 2016 2015 2014 2013 2012 2011 2010 2009 2008

Market Cap

308 M 419 M 526 M 234 M 163 M 93.9 M 251 M 581 M 223 M 132 M 22.8 M - - -

Shares

99.3 M 99.8 M 83.2 M 63.2 M 55.4 M 53.7 M 52.4 M 48.4 M 37.9 M 30.5 M 28.3 M 23.2 M 20.2 M -

Historical Prices

3.1 4.2 6.32 3.7 2.95 1.75 4.79 12 5.89 4.31 0.805 - - -

Net Income

84.9 M 25.7 M -15.3 M -33.9 M 5.28 M -15.9 M 10.2 M -17.6 M -57.4 M 1.65 M -23.3 M -13 M 33 M -

Revenue

167 M 156 M 111 M 18 M 12.5 M 3.93 M 32.2 M 2.55 M 11.4 M 54.5 M 3.26 M 3.4 M 62.8 M -

Cost of Revenue

23.4 M 24.7 M 21.6 M 15.8 M 19.5 M 11.3 M 8.1 M 4.94 M 2.08 M 1.91 M 1.76 M 839 K 2.04 M -

Gross Profit

- 33.9 M 24.4 M 14 M 7.28 M 1.63 M 29.6 M -516 K 3.6 M 19.1 M 1.51 M - - -

Operating Income

37.1 M 33 M 3.74 M -4.45 M -14.3 M -15.2 M 11 M -18.4 M -56.4 M 7.06 M -27 M -16.3 M 40.1 M -

Interest Expense

-6 K -3 K 19 M 10.2 M 8.58 M 3.27 M 2.52 M 2.02 M 903 K 33 K 10.7 K 25.9 K -15.1 K -

EBITDA

37.3 M 33.5 M 5.58 M -3.71 M -13.6 M -14.8 M 11.3 M -18.2 M -56.2 M 7.53 M -26.5 M -15.9 M 40.3 M -

Operating Expenses

106 M 98.8 M 86.1 M 63.5 M 71.9 M 68.2 M 75.3 M 72.7 M 65.7 M 45.6 M 28.5 M 18.9 M 20.6 M -

General and Administrative Expenses

106 M 98.8 M 86.1 M 58.6 M 58.9 M 49.3 M 54.7 M 38.5 M 12.3 M 10.1 M 7.61 M 7.91 M 8.4 M -

All numbers in USD currency

Quarterly Income Statement BioDelivery Sciences International

2022-Q4 2022-Q3 2022-Q2 2022-Q1 2021-Q4 2021-Q3 2021-Q2 2021-Q1 2020-Q4 2020-Q3 2020-Q2 2020-Q1 2019-Q4 2019-Q3 2019-Q2 2019-Q1 2018-Q4 2018-Q3 2018-Q2 2018-Q1 2017-Q4 2017-Q3 2017-Q2 2017-Q1 2016-Q4 2016-Q3 2016-Q2 2016-Q1 2015-Q4 2015-Q3 2015-Q2 2015-Q1 2014-Q4 2014-Q3 2014-Q2 2014-Q1 2013-Q4 2013-Q3 2013-Q2 2013-Q1 2012-Q4 2012-Q3 2012-Q2 2012-Q1 2011-Q4 2011-Q3 2011-Q2 2011-Q1

Shares

- - - - 98.9 M 98.7 M 98.8 M 101 M 101 M 101 M 100 M 97.1 M 96.2 M 89.6 M 83.8 M 71.3 M 70.8 M 64.9 M 59.4 M 58.1 M 55.9 M 55.6 M 55.4 M 54.5 M 54.1 M 53.8 M 53.6 M 52.2 M 52.7 M 52.5 M 52.4 M 51.9 M 51.6 M 49.6 M 48.5 M 44 M 38.2 M 38.1 M 38 M 37.5 M 37.5 M 30.1 M 29.7 M 29.6 M 29.6 M 29.6 M 29.6 M 25.1 M

Net Income

- - - - - 6.67 M 9.06 M 5.24 M 10.2 M 9.38 M 1.16 M 4.97 M -696 K 354 K -11.1 M -3.83 M -7.01 M -6.38 M -9.77 M -10.7 M -16.2 M -12 M -14.9 M 48.3 M -15.9 M -16 M -16.5 M -18.7 M 10.2 M -20.4 M -19.2 M -8.19 M -17.6 M -36.6 M -11.3 M -4.64 M -12.8 M -18.5 M -13.4 M -12.7 M 8.6 M -17.5 M 3.78 M 6.75 M - -5.12 M -5.1 M -9.02 M

Revenue

- - - - - 41.1 M 41.4 M 41 M 42.2 M 39.4 M 36.6 M 38.3 M 31.6 M 30.3 M 29.7 M 19.8 M 18 M 14.2 M 12.2 M 11.3 M 12.5 M 11.3 M 8.74 M 29.5 M 3.93 M 3.57 M 5 M 3.04 M 32.2 M 1.24 M 1.73 M 13.1 M 2.55 M 1.82 M 13.9 M 20.7 M 3.97 M 3 M 2.76 M 1.62 M 19.9 M 1.88 M 16.3 M 16.5 M - 2.66 M 38.4 K 229 K

Cost of Revenue

- - - - - 6.36 M 4.28 M 5.82 M - 5.38 M 5.44 M 5.56 M - 5.35 M 4.92 M 4.05 M - 3.78 M 4.57 M 3.42 M - 4.44 M 4.17 M 5.64 M - 2.31 M 4.09 M 2.55 M - 1.7 M 2.62 M 1.12 M - 463 K 687 K 726 K - 643 K 690 K 375 K - 375 K 375 K 375 K - 1.51 M -426 K 297 K

Gross Profit

- - - - - - - - 33.9 M 34.1 M 31.1 M 32.7 M 24.4 M 25 M 24.8 M 15.7 M 14 M 10.4 M 7.61 M 7.87 M 7.28 M 6.81 M 4.57 M 23.8 M 1.63 M 1.26 M 910 K 490 K 29.6 M -464 K -888 K 11.9 M -516 K 1.36 M 13.2 M 20 M 3.6 M 2.35 M 2.07 M 1.25 M 19.1 M 1.5 M 15.9 M 16.1 M - - - -

Operating Income

- - - - - 9.26 M 11.4 M 7.44 M 12.5 M 11.6 M 2.94 M 5.98 M 613 K 1.6 M 2.8 M -1.27 M -4.45 M -3.81 M -7.27 M -8.12 M -14.3 M -10 M -13 M 7.9 M -15.2 M -15.2 M -15.6 M -17.9 M 11 M -19.7 M -18.7 M -7.8 M -18.4 M -19.1 M -2.04 M 713 K -11.8 M -17.1 M -13.8 M -13.7 M 5.41 M -14.1 M 7.15 M 8.56 M - -7.67 M -6.21 M -8.54 M

Interest Expense

- - - - - 1.98 M 2 M 1.98 M - 2.01 M 1.69 M 1.29 M - 1.23 M 13.9 M 2.56 M - 2.57 M 2.52 M 2.5 M - 1.89 M 1.88 M 2.89 M - 786 K 914 K 778 K - 785 K -3 K 27 K - 2.13 K 9.05 K 23.3 K - -35.4 K -95.5 K -23.2 K - 16.4 K 50.3 K -3.46 K - 15.2 K 11.9 K -27.9 K

EBITDA

- - - - - 9.36 M 11.4 M 7.46 M 12.5 M 12.1 M 3.38 M 6 M 613 K 1.85 M 2.97 M -1.19 M -4.45 M -3.61 M -7.07 M -7.89 M -14.3 M -9.84 M -12.9 M 8.01 M -15.2 M -15.1 M -15.5 M -17.9 M 11 M -19.6 M -18.6 M -7.72 M -18.4 M -18.3 M -1.53 M 1.04 M -11.8 M -16.1 M -13.1 M -13.3 M 5.41 M -12.9 M 7.89 M 8.94 M - -6.68 M -5.55 M -8.21 M

Operating Expenses

- - - - - 25.5 M 25.8 M 27.8 M - 22.5 M 28.2 M 26.7 M - 23.4 M 22 M 17 M - 14.2 M 14.9 M 16 M - 16.9 M 17.6 M 15.9 M - 16.5 M 16.5 M 18.4 M - 19.2 M 17.8 M 19.7 M - 20.4 M 15.2 M 19.3 M - 19.4 M 15.9 M 15 M - 15.6 M 8.78 M 7.58 M - 8.83 M 6.67 M 8.47 M

General and Administrative Expenses

- - - - - 25.5 M 25.8 M 27.8 M - 22.5 M 28.2 M 26.7 M - 23.4 M 22 M 17 M - 13.5 M 14 M 13.5 M - 14.9 M 16 M 13.3 M - 12.1 M 12.5 M 13.1 M - 14.7 M 13.3 M 13.2 M - 13.6 M 7.25 M 4.62 M - 3.04 M 3.11 M 2.91 M - 2.99 M 2.21 M 2.84 M - 2.59 M 1.93 M 1.76 M

All numbers in USD currency

Financial statements are the primary tool companies use to inform stakeholders about their financial position, performance, and changes in capital structure. It is a kind of "business language" understood by investors, creditors, tax authorities, and other participants in the economic environment.

Main types of financial statements BioDelivery Sciences International BDSI
  1. Income Statement
    Shows income, expenses, and resulting profit or loss over a specific period. Helps assess business profitability.
  2. Balance Sheet
    Reflects a company’s assets, liabilities, and equity as of a specific date. It’s a snapshot of what the company owns and owes.
    Assets — everything the company owns (cash, equipment, buildings, accounts receivable, etc.).
    Liabilities — debts and other external sources of financing.
    Equity — owners' capital and retained earnings.
  3. Cash Flow Statement
    Reveals how the company earns and spends money in three areas: operating, investing, and financing activities.
International reporting standards
  • IFRS — International Financial Reporting Standards, applicable to public and multinational companies.
  • GAAP — Generally Accepted Accounting Principles used in the United States.
  • RAS — Russian Accounting Standards, used domestically in Russia.

Financial reporting BioDelivery Sciences International plays a crucial role for investors as it serves as an objective source of information about a company's current state. Based on the reports, one can determine whether a company is growing, stagnating, or losing market share. This allows investors to identify both promising and problematic assets in a timely manner.

In addition, financial data provides a basis for forecasting future returns. Historical trends in revenue, profit, and cash flow help evaluate potential dividends, the likelihood of stock price growth, and overall investment risk.

Transparent and accurate reporting is also an indicator of a company’s maturity and managerial responsibility. Such openness builds investor confidence and simplifies investment decision-making, especially when comparing multiple companies.

Finally, financial statements enable high-quality comparative analysis. They allow companies to be evaluated against each other in terms of profitability, debt levels, margins, and other key metrics — which is particularly important when choosing the best investment options within an industry or market segment.

Financial statements of other stocks in the Biotechnology industry

Issuer Price % 24h Market Cap Country
Celsion Corporation Celsion Corporation
CLSN
- -6.63 % $ 13.9 M usaUSA
FSD Pharma FSD Pharma
HUGE
- 5743.5 % $ 69.7 M canadaCanada
Qilian International Holding Group Limited Qilian International Holding Group Limited
QLI
- -6.08 % $ 184 M chinaChina
Happiness Biotech Group Limited Happiness Biotech Group Limited
HAPP
- 1.35 % $ 17.8 M chinaChina
Synthetic Biologics Synthetic Biologics
SYN
- 1.32 % $ 16.2 M usaUSA
Dynavax Technologies Corporation Dynavax Technologies Corporation
DVAX
- - $ 2.02 B usaUSA
BioXcel Therapeutics BioXcel Therapeutics
BTAI
$ 1.19 5.31 % $ 14.5 M usaUSA
Burford Capital Limited Burford Capital Limited
BUR
$ 4.37 0.23 % $ 958 M britainBritain
I-Mab I-Mab
IMAB
- - $ 866 M chinaChina
BeyondSpring BeyondSpring
BYSI
$ 0.84 34.27 % $ 34.5 M usaUSA
Corner Growth Acquisition Corp. Corner Growth Acquisition Corp.
COOL
- -0.89 % $ 114 M usaUSA
AgeX Therapeutics AgeX Therapeutics
AGE
- -10.17 % $ 12.2 K usaUSA
Alexion Pharmaceuticals, Inc. Alexion Pharmaceuticals, Inc.
ALXN
- - $ 40.3 B usaUSA
Genfit SA Genfit SA
GNFT
- 2.54 % $ 160 B franceFrance
Biophytis SA Biophytis SA
BPTS
- -13.47 % $ 169 M franceFrance
Cerus Corporation Cerus Corporation
CERS
$ 2.98 4.93 % $ 568 M usaUSA
Compugen Ltd. Compugen Ltd.
CGEN
$ 2.41 4.17 % $ 225 M israelIsrael
CureVac N.V. CureVac N.V.
CVAC
- - $ 867 M germanyGermany
EyeGate Pharmaceuticals, Inc. EyeGate Pharmaceuticals, Inc.
EYEG
- -1.52 % $ 24.7 M usaUSA
Athira Pharma Athira Pharma
ATHA
- - $ 269 M usaUSA
BiondVax Pharmaceuticals Ltd. BiondVax Pharmaceuticals Ltd.
BVXV
- 0.74 % $ 768 M israelIsrael
Abcam plc Abcam plc
ABCM
- - $ 4.9 B britainBritain
Завод ДИОД Завод ДИОД
DIOD
- - - russiaRussia
Galera Therapeutics Galera Therapeutics
GRTX
- -32.59 % $ 7.61 M usaUSA
Midatech Pharma plc Midatech Pharma plc
MTP
- -18.52 % $ 27.3 M britainBritain
Hepion Pharmaceuticals Hepion Pharmaceuticals
HEPA
- -18.79 % $ 39.3 K usaUSA
ARCA biopharma ARCA biopharma
ABIO
- 1052.0 % $ 415 M usaUSA
MorphoSys AG MorphoSys AG
MOR
- 2.43 % $ 254 M germanyGermany
Champions Oncology Champions Oncology
CSBR
$ 5.1 2.63 % $ 70.5 M usaUSA
Affimed N.V. Affimed N.V.
AFMD
- -34.95 % $ 21.5 M germanyGermany
AnPac Bio-Medical Science Co., Ltd. AnPac Bio-Medical Science Co., Ltd.
ANPC
- -1.58 % $ 28.1 M chinaChina
Celyad Oncology SA Celyad Oncology SA
CYAD
- - $ 12.5 M belgiumBelgium
Adial Pharmaceuticals Adial Pharmaceuticals
ADIL
$ 3.98 1.86 % $ 2.66 M usaUSA
Generation Bio Co. Generation Bio Co.
GBIO
- - $ 344 M usaUSA
Akero Therapeutics Akero Therapeutics
AKRO
- - $ 3.67 B usaUSA
AnaptysBio AnaptysBio
ANAB
$ 58.47 4.37 % $ 1.68 B usaUSA
Anika Therapeutics Anika Therapeutics
ANIK
$ 21.5 1.56 % $ 308 M usaUSA
Cyclacel Pharmaceuticals Cyclacel Pharmaceuticals
CYCCP
- -4.36 % $ 27 M usaUSA
Gracell Biotechnologies Gracell Biotechnologies
GRCL
- - $ 3.37 B chinaChina
Aurinia Pharmaceuticals Aurinia Pharmaceuticals
AUPH
$ 15.47 1.91 % $ 2.08 B canadaCanada
GlycoMimetics GlycoMimetics
GLYC
- 9357.83 % $ 1.01 B usaUSA
Aeterna Zentaris Aeterna Zentaris
AEZS
- 5.93 % $ 314 M canadaCanada
AVROBIO AVROBIO
AVRO
- 1083.1 % $ 745 M usaUSA
BeiGene, Ltd. BeiGene, Ltd.
BGNE
- 0.49 % $ 251 B cayman-islandsCayman-islands
Bicycle Therapeutics plc Bicycle Therapeutics plc
BCYC
$ 3.9 0.24 % $ 270 M britainBritain
Beam Therapeutics Beam Therapeutics
BEAM
$ 26.75 0.91 % $ 2.65 B usaUSA
AIkido Pharma AIkido Pharma
AIKI
- 1.93 % $ 17.4 M usaUSA
Aeglea BioTherapeutics Aeglea BioTherapeutics
AGLE
- - $ 1.01 B usaUSA
BioMarin Pharmaceutical BioMarin Pharmaceutical
BMRN
$ 67.36 0.99 % $ 12.9 B usaUSA
Aptose Biosciences Aptose Biosciences
APTO
- -45.71 % $ 1.2 M canadaCanada